TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT01239758

Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Cause of deathSafety Automatic label, confidence 0.9, unverified. How labels are made.
“This study was terminated based on preliminary safety data.”

The sponsor’s own words in the registry.

Life of this trial

201020112012Started2010-10Registered2010-11-01Stopped2011-05

Vital statistics

Status
Terminated
Phase
Phase 2
Sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Sponsor type
Industry
Conditions
Duchenne Muscular Dystrophy
Interventions
ACE-031 (Extension of cohort 1 from core study, A031-03); ACE-031 (Extension of cohort 2 from core study, A031-03); ACE-031 (Extension of cohort 3 from core study, A031-03)
Participants
11
Sites
4
Countries
Canada

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.